Activity Information

The Materials to Increase Minority Participation in Clinical Trials (MIMICT) II is a free activity comprised of four modules to help rheumatologists and non-rheumatology providers understand the reasons for low participation among minorities in lupus clinical trials. With MIMICT II, you receive:

• Four modules
• 10 multiple-choice questions with in-depth answer rationales
• Up to 1.0 ABIM MOC points and 1.0 AMA PRA Category 1 Credit(s)™ with a passing score of 80% or higher

Target Audience

Rheumatologists, primary care physicians, PAs, NPs, students/residents/fellows, nephrologists, and dermatologists

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

• Discuss clinical trials basics
• Recognize lupus symptoms and lupus-related health disparities
• Recognize the definition of a clinical trial referral and discuss the clinical trial referral process, as well as how clinical trials sites and providers can utilize the MIMICT model
• Identify communication strategies to build trust between patients, providers, and principal investigators
• Identify culturally-competent communication strategies to use when interacting with patients

Registration Fees

Registration is complimentary.

CME and MOC Information

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The ACR designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity you provide the ACR permission to share completion data with the ACCME and the certifying board(s).

Faculty and Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience all financial relationships with ineligible companies any financial or other relationship(s) with a ineligible company including, but not limited to:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria includes speakers bureau, symposia, and expert witness
7. Independent contractor
8. Ownership Interest
9. Royalties
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

Corporate Support

The ACR thanks the U.S. Department of Health and Human Services, Office of Minority Health (HHS, OMH) for supporting the MIMICT II project with Grant Numbers 1 CPIMP171138 and 1 CPIMP181166. 

Disclosures

• Allen Anandarajah, MD (Planner) – No relevant financial information to disclose
• Saira Z. Sheikh, MD (Planner) – GSK², Aurinia Pharmaceuticals², AstraZeneca², Lilly USA², LLC, Biogen², Cabaletta Bio², Pfizer⁵
• J. Chistopher Reed, JD (Planner) – GlaxoSmithKline²
• Tessa R. Englund, PhD, MPH (Reviewer) – No relevant financial information to disclose
• Rosalind Ramsey-Goldman, MD, DrPH (Planner) – Cabaletta², BMS², Exagen², Merck², Upstart Research Consulting², Biogen², Ampel Solutions²
• Michelle Wimes, JD (Reviewer) – No relevant financial information to disclose